Institute for Research on Cancer and Aging of Nice (IRCAN), INSERM, Université Côte d'Azur, CNRS, Nice, France.
The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK.
Mol Cell. 2019 May 16;74(4):651-663.e8. doi: 10.1016/j.molcel.2019.03.002. Epub 2019 Apr 3.
Accumulating evidence supports the role of the DNA damage response (DDR) in the negative regulation of tumorigenesis. Here, we found that DDR signaling poises a series of epigenetic events, resulting in activation of pro-tumorigenic genes but can go as far as reactivation of the pluripotency gene OCT4. Loss of DNA methylation appears to be a key initiating event in DDR-dependent OCT4 locus reactivation although full reactivation required the presence of a driving oncogene, such as Myc and macroH2A downregulation. Using genetic-lineage-tracing experiments and an in situ labeling approach, we show that DDR-induced epigenetic reactivation of OCT4 regulates the resistance to chemotherapy and contributes to tumor relapse both in mouse and primary human cancers. In turn, deletion of OCT4 reverses chemoresistance and delays the relapse. Here, we uncovered an unexpected tumor-promoting role of DDR in cancer cell reprogramming, providing novel therapeutic entry points for cancer intervention strategies.
越来越多的证据支持 DNA 损伤反应 (DDR) 在肿瘤发生的负调控中的作用。在这里,我们发现 DDR 信号引发了一系列表观遗传事件,导致促肿瘤基因的激活,但也可以进一步激活多能性基因 OCT4。尽管完全激活 OCT4 基因需要存在驱动癌基因,如 Myc 和 macroH2A 的下调,但 DNA 甲基化的缺失似乎是 DDR 依赖性 OCT4 基因座重新激活的关键起始事件。通过遗传谱系追踪实验和原位标记方法,我们表明 DDR 诱导的 OCT4 表观遗传再激活调节了对化疗的耐药性,并导致了小鼠和原发性人类癌症的肿瘤复发。反过来,OCT4 的缺失逆转了化疗耐药性并延迟了复发。在这里,我们揭示了 DDR 在肿瘤细胞重编程中的一个意想不到的促癌作用,为癌症干预策略提供了新的治疗切入点。